L V Rubinstein

Neural computing in cancer drug development: predicting mechanism of action.

J N Weinstein, K W Kohn, M R Grever, 1992, Science.

Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of action.

D Faraggi, J N Weinstein, K W Kohn, 1994, Statistics in medicine.

Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.

M R Grever, L V Rubinstein, A D Koutsoukos, 1994, Cancer research.

Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

L V Rubinstein, R. Ginsberg, L. Rubinstein, 1995, The Annals of thoracic surgery.

Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.

W G Alvord, L V Rubinstein, K D Paull, 1996, Cancer research.

Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.

L V Rubinstein, D A Scudiero, K D Paull, 1990, Journal of the National Cancer Institute.

Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.

L V Rubinstein, D A Scudiero, A D Koutsoukos, 1992, Cancer research.

A comparison of two phase I trial designs.

L V Rubinstein, E L Korn, D. Midthune, 1994, Statistics in medicine.